Researchers and clinicians are working miracles in medicine these days because of breakthroughs in therapies that have received crucial backing from the alternative investment industry.
There is much more work to be done, and that’s what drives the staff of RTW Investments. “This is the start of an amazing next generation of innovation,” said Stephanie Sirota, chief business officer at RTW. “You have a wonderful advantage when you start evaluating the science, before it is even investible.”
These innovations have included the rapid development of safe and effective RNA vaccines against COVID 19 and . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
